Plaquenil: A Comprehensive Overview of Hydroxychloroquine > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Plaquenil, the brand name for hydroxychloroquine, is an antimalarial medication that has been used for decades primarily to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It belongs to the 4-aminoquinoline class of drugs and is structurally related to chloroquine. While originally developed as an antimalarial agent, its immunomodulatory properties have made it a cornerstone in rheumatology.

History and Development

Hydroxychloroquine was first synthesized in 1946 by adding a hydroxyl group to chloroquine, 120mg (http://verticenorte.com/) which reduced its toxicity while retaining efficacy. It was approved by the U.S. Food and Drug Administration (FDA) in 1955. During the 20th century, it became widely used for malaria prophylaxis and treatment, but its role expanded as physicians recognized its benefits in autoimmune conditions. In the early 21st century, it gained global attention during the COVID-19 pandemic as a potential treatment, though subsequent large trials showed no significant benefit and highlighted safety concerns.

Mechanism of Action

The exact mechanism of hydroxychloroquine in autoimmune diseases is not fully understood, but several actions are proposed. It accumulates in lysosomes, raising their pH, which interferes with antigen presentation and reduces the activation of Toll-like receptors (TLRs) involved in innate immunity. It also inhibits the production of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α). Additionally, hydroxychloroquine reduces T-cell activation and impairs the function of dendritic cells. For malaria, it inhibits the polymerization of heme into hemozoin, leading to toxic free heme accumulation that kills the parasite.

Clinical Uses

1. Systemic Lupus Erythematosus (SLE): Plaquenil is a first-line treatment for mild to moderate SLE. It reduces disease flares, protects against organ damage, and improves long-term survival. It is particularly effective for cutaneous and musculoskeletal symptoms. For pregnant women with SLE, it is considered safe and recommended to prevent flares and reduce the risk of neonatal lupus.
   
2. Rheumatoid Arthritis (RA): Hydroxychloroquine is used as a disease-modifying antirheumatic drug (DMARD). It is often combined with methotrexate or sulfasalazine for moderate RA. Its effects are slow (onset may take 6–12 weeks) and it helps reduce joint pain and swelling.
   
3. Antiphospholipid Syndrome (APS): Used as an adjunct therapy to reduce thrombotic risk.
   
4. Malaria: Both prophylaxis and treatment of chloroquine-sensitive Plasmodium vivax and P. ovale infections. It is not recommended for P. falciparum due to widespread resistance.
   
5. Other Off-Label Uses: Sarcoidosis, Sjögren’s syndrome, and porphyria cutanea tarda (PCT) have shown benefit.
   
   

For RA and SLE, typical starting doses are 200–400 mg per day (tablets are 200 mg). The standard maximum dose is 6.5 mg/kg of ideal body weight per day, but not exceeding 400 mg/day to reduce risk of retinal toxicity. For malaria, dosing varies by indication (prophylaxis: 400 mg once weekly; treatment: 800 mg initially, then 400 mg at 6, 24, and 48 hours). It is well absorbed orally, with a long half-life (~40 days) allowing once-daily or weekly dosing.

Side Effects and Safety

Common side effects include gastrointestinal upset (nausea, diarrhea, anorexia), headache, and dizziness. These often subside with continued use or dose adjustment. More serious but rare effects include:

• Retinal toxicity: The most significant long-term toxicity. Hydroxychloroquine accumulates in the retinal pigment epithelium, causing irreversible retinopathy. Risk increases with cumulative dose (typically after >5 years of use or >1000 grams total dose) and in patients with renal impairment or concomitant tamoxifen use. Baseline and yearly ophthalmic screening (including optical coherence tomography and visual field tests) is recommended.
  
• Cardiotoxicity: Prolonged QT interval and cardiomyopathy have been reported, particularly at high doses or with certain predispositions.
  
• Hypoglycemia: Can potentiate insulin effects; blood glucose should be monitored in diabetics.
  
• Skin: Rarely, drug eruptions or pigmentation changes (gray-blue discoloration of shins and face).
  
• Hematologic: Aplastic anemia, agranulocytosis, and thrombocytopenia are very rare.
  
• Psychiatric: Agitation, psychosis, or suicidal ideation (rare, mostly in patients with underlying mental health issues).
  
  

Hydroxychloroquine has significant interactions with antiarrhythmics (e.g., amiodarone, procainamide) that can increase QT prolongation risk. It may reduce the efficacy of antiepileptic drugs and increase levels of digoxin and metoprolol. Caution is needed when combined with other QT-prolonging drugs.

Contraindications

Absolute contraindications include known hypersensitivity to 4-aminoquinolines and history of retinopathy from hydroxychloroquine or chloroquine. Relative contraindications include pre-existing retinal disease, severe G6PD deficiency (though usually safe at standard doses), and porphyria.

Pregnancy and Lactation

Hydroxychloroquine is pregnancy category C but is considered safe and beneficial for women with SLE or APS. It does not appear to increase congenital malformations and may reduce adverse pregnancy outcomes. It is also excreted in breast milk in low amounts; the American Academy of Pediatrics considers it compatible with breastfeeding.

Controversies and Recent Research

During the COVID-19 pandemic, hydroxychloroquine was widely promoted as a potential treatment based on preliminary in vitro and small observational studies. However, subsequent large randomized controlled trials (e.g., RECOVERY, SOLIDARITY) showed no reduction in mortality or clinical improvement, and increased risks of cardiac arrhythmias were noted. The FDA revoked its emergency use authorization in 2020. Ongoing research continues to explore hydroxychloroquine for other viral infections, as an anti-inflammatory in cancer immunotherapy, and for its effects on metabolic parameters.

Conclusion

Plaquenil (hydroxychloroquine) remains an essential, well-tolerated, and relatively safe medication for autoimmune diseases when used with appropriate monitoring. Its role in malaria is diminishing due to resistance, but its immunomodulatory benefits in SLE and RA are undisputed. Clinicians must weigh long-term risk of retinal toxicity through regular screening. The drug’s reputation was marred by the pandemic hype, but its established efficacy in rheumatology continues to serve millions of patients worldwide.